For extrapulmonary neuroendocrine carcinoma that has grown through platinum chemotherapy, there is no standard next treatment. At NANETS 2026, the DLL3-targeted drug zoci shrank tumors in 40% of patients, with responses lasting a median of 5.6 months and fewer than 1% stopping for side effects. What the early data show — and what they don't.